Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P22102
UPID:
PUR2_HUMAN
Alternative names:
-
Alternative UPACC:
P22102; A8K945; A8KA32; D3DSF3; D3DSF4; O14659; Q52M77
Background:
The Trifunctional purine biosynthetic protein adenosine-3 plays a pivotal role in the 'de novo' inosine monophosphate biosynthetic pathway. This enzyme catalyzes three distinct reactions, showcasing its versatility and essential function in purine metabolism.
Therapeutic significance:
Understanding the role of Trifunctional purine biosynthetic protein adenosine-3 could open doors to potential therapeutic strategies. Its critical function in purine synthesis highlights its potential as a target for drug discovery, aiming to modulate purine levels in various diseases.